Clinical Trial Update: Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia

View source ↗

Summary

Expanded access program for nilotinib (AMN107) in adults with imatinib-resistant or intolerant chronic myeloid leukemia has ended; the program is no longer avai…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Nilotinib (nilotinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Myeloid Leukemia | Status: NO_LONGER_AVAILABLE